KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Other Non-Current Liabilities (2016 - 2025)

Nektar Therapeutics has reported Other Non-Current Liabilities over the past 16 years, most recently at $8.6 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $8.6 million for Q4 2025, up 19.11% from a year ago — trailing twelve months through Dec 2025 was $8.6 million (up 19.11% YoY), and the annual figure for FY2025 was $8.6 million, up 19.11%.
  • Other Non-Current Liabilities for Q4 2025 was $8.6 million at Nektar Therapeutics, up from $5.0 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for NKTR hit a ceiling of $27.7 million in Q4 2021 and a floor of $2.1 million in Q2 2022.
  • Median Other Non-Current Liabilities over the past 5 years was $5.2 million (2023), compared with a mean of $6.7 million.
  • Biggest five-year swings in Other Non-Current Liabilities: crashed 72.77% in 2022 and later skyrocketed 147.64% in 2023.
  • Nektar Therapeutics' Other Non-Current Liabilities stood at $27.7 million in 2021, then crashed by 72.77% to $7.6 million in 2022, then plummeted by 38.62% to $4.6 million in 2023, then surged by 56.22% to $7.2 million in 2024, then grew by 19.11% to $8.6 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $8.6 million (Q4 2025), $5.0 million (Q3 2025), and $5.6 million (Q2 2025) per Business Quant data.